Low or depleted magnesium levels place people with diabetes and metabolic syndrome (MetSyn) at higher risk of worsening glycemic control and insulin resistance because magnesium is essential for normal glucose metabolism and beta-cell function. When magnesium is low, these metabolic pathways become less efficient, amplifying blood sugar instability, lipid abnormalities, and other MetSyn features. Even moderate depletion can accelerate type 2 diabetes and MetSyn-related complications, underscoring the need for monitoring magnesium status in these vulnerable groups. This medication is commonly used for Hypertension.
Gommers LM, Hoenderop JG, Bindels RJ, de Baaij JH. Hypomagnesemia in Type 2 Diabetes: A Vicious Circle? Diabetes. 2016 Jan;65(1):3-13. Ozcaliskan Ilkay H, Sahin H, Tanriverdi F, Samur G. Association Between Magnesium Status, Dietary Magnesium Intake, and Metabolic Control in Patients with Type 2 Diabetes Mellitus. J Am Coll Nutr. 2019 Jan;38(1):31-39. Mooren FC. Magnesium and disturbances in carbohydrate metabolism. Diabetes Obes Metab. 2015 Sep;17(9):813-23. Paladiya R, Pitliya A, Choudhry AA, Kumar D, Ismail S, Abbas M, Naz S, Kumar B, Jamil A, Fatima A. Association of Low Magnesium Level With Duration and Severity of Type 2 Diabetes. Cureus. 2021 May 27;13(5):e15279. Ju SY, Choi WS, Ock SM, Kim CM, Kim DH. Dietary magnesium intake and metabolic syndrome in the adult population: dose-response meta-analysis and meta-regression. Nutrients. 2014 Dec 22;6(12):6005-19.
Some side effects may be linked to nutrient depletion caused by this medication.
An increased excretion of potassium can occur in people taking calcium channel blocker drugs like felodipine. Supplementation may need to be considered if blood levels of potassium are low.
Studies suggest that Felodipine, a type of calcium channel blocker (CCB), may increase the excretion of calcium in the urine. While the long-term effects on bone health are unclear, some healthcare professionals suggest calcium supplementation for patients taking felodipine, especially those at higher risk of osteoporosis.
Research suggests that Felodipine, a type of calcium channel blocker (CCB), may increase the excretion of magnesium in the urine. This can potentially lead to magnesium deficiency. Studies have shown an increase in fractional excretion of magnesium following felodipine treatment, and the drug may also alter how magnesium moves across red blood cell membranes. Therefore supplementation with magnesium should be considered when on this therapy.